Poorer Cognitive Performance in Patients with Essential Tremor-Parkinsonâ€™s Disease vs. Patients with Parkinsonâ€™s Disease by Elan D. Louis et al.
ORIGINAL RESEARCH
published: 18 May 2015
doi: 10.3389/fneur.2015.00106
Edited by:
Oscar Arias-Carrión,
Hospital General Dr. Manuel Gea
González, Mexico
Reviewed by:
Graziella Madeo,
University of Rome Tor Vergata, Italy
Tifei Yuan,
Nanjing Normal University, China
*Correspondence:
Elan D. Louis,
Department of Neurology, Yale
University School of Medicine,
15 York Street, P. O. Box 208018,
New Haven, CT 06520-8018, USA
elan.louis@yale.edu
Specialty section:
This article was submitted to
Movement Disorders, a section of the
journal Frontiers in Neurology
Received: 23 March 2015
Accepted: 28 April 2015
Published: 18 May 2015
Citation:
Louis ED, Rohl B, Collins K and
Cosentino S (2015) Poorer cognitive
performance in patients with essential
tremor-Parkinson’s disease vs.
patients with Parkinson’s disease.
Front. Neurol. 6:106.
doi: 10.3389/fneur.2015.00106
Poorer cognitive performance in
patients with essential
tremor-Parkinson’s disease vs.
patients with Parkinson’s disease
Elan D. Louis1,2*, Brittany Rohl1, Kathleen Collins1 and Stephane Cosentino3,4
1 Division of Movement Disorders, Department of Neurology, Yale School of Medicine, Yale University, New Haven, CT,
USA, 2 Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, USA,
3 Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA, 4 Taub Institute for
Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York,
NY, USA
Background: Patients with essential tremor (ET) seem to be at increased risk of
developing Parkinson’s disease (PD). Surprisingly, little has been written about this clinical
entity, ET-PD. Cognitive dysfunction is a well-known feature of PD, and can also be an
issue in patients with ET. Whether the presence of the combined diagnosis, ET-PD, is
associated with additive cognitive effects as compared with PD has not been studied.
Methods: Thirty ET-PD patients and 53 age-matched PD patients were enrolled in a
clinical-epidemiological study. Two cognitive screens, the Telephone Interview for Cog-
nitive Status (TICS, score=0–41) and Folstein Mini-Mental State Examination (MMSE;
range 0–30), were administered.
Results: The MMSE score was lower in ET-PD than PD [26.53.1 (median 28.0) vs.
28.42.2 (median 29.0), p=0.001]. The TICS score was lower in ET-PD than PD
[31.73.9 (32.0) vs. 35.02.0 (35.0), p<0.001]. Subscores of these tests that related
to orientation (p<0.001), language (p<0.001), and working memory (p=0.001) were
lower in ET-PD than PD, whereas the delayed memory subscore was only marginally
lower in ET-PD than PD (p=0.06), and the two groups did not differ with respect to
the motor/construction subscore (p=0.22). Both global cognitive scores were inversely
correlated with disease duration (for MMSE score, Spearman’s r= 0.46, p<0.001; for
TICS score, Spearman’s r= 0.53, p<0.001).
Conclusion: The combined diagnosis, ET-PD, seemed to be associated with additive
cognitive effects as compared with PD alone.
Keywords: essential tremor, Parkinson’s disease, cognition, clinical, dementia
Introduction
Patients with essential tremor (ET) seem to be at increased risk of developing Parkinson’s disease
(PD) (1). Prospective, longitudinal, epidemiological data estimate a four- to five-fold increased
risk (1).
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Despite this association, surprisingly, little has been written
about this clinical entity, “ET-PD,” with only two small case series
[n= 22 (2), n= 53 (3)], both based on retrospective chart review.
The cognitive features of this combination disorder have not been
studied, as prior reports focused on tremor and other motor
features.
Cognitive dysfunction is awell-known feature of PD (4). Recent
work indicates that cognitive dysfunction may also be an issue
in patients with ET (5), although data are limited. The types of
cognitive deficits are not dissimilar in the two disorders, with
executive dysfunction and deficits in memory being prominent
(5). Whether the presence of the combined diagnosis is associated
with additive cognitive effects is not known, but seems plausible.
As part of a prospective, clinical–epidemiological study, we
performed a standardized, structured clinical evaluation of 30 ET-
PD patients, comparing them to 53 age-matched PD patients.
As part of that evaluation, patients underwent several cognitive
screens. The goal of these analyses was to compare the cogni-
tive performance in these two patient groups, with the a priori
hypothesis that ET-PD patients would have poorer performance
than their counterparts with PD alone.
Materials and Methods
Participants
Participants were enrolled in a clinical–epidemiological study
of movement disorders at the Neurological Institute, Columbia
University Medical Center (CUMC) (2009–2014) (6). The study
assessed the role of environmental toxins in disease etiology; it
also evaluated a wide range of clinical features across movement
disorders. ET-PD and PD patients seen in the most recent 5 years
were identified from a computerized billing database at the Center
for Parkinson’s Disease and Other Movement Disorders at the
Institute. Each patient had received a diagnosis of PD or ET-
PD from their treating neurologist at the Institute. One of the
authors (Elan D. Louis) reviewed the office records of identified
patients; those with diagnoses of or physical signs consistent with
other movement disorders were excluded. During the review, the
most recent Hoehn and Yahr score (7), daily dose (milligrams) of
levodopa, and other data were recorded.
The CUMC Internal Review Board approved study procedures.
Signed informed consent was obtained upon enrollment.
Study Evaluation
During the initial enrollment telephone call, the 10-min Tele-
phone Interview for Cognitive Status [TICS, score= 0–41 (no
impairment)] was administered to all participants (8), although
no participants were excluded based on their score. An in-person
clinical assessment was then performed, during which a trained
research assistant administered a series of structured question-
naires, which elicited data on (1) demographic variables, (2) gen-
eral medical health (Cumulative Illness Rating Scale score (9)
[range= 0–42 (maximum)], total number of prescriptionmedica-
tions), (3) disease duration (e.g., duration of first motor symptoms
in PD and duration of initial action tremor in ET-PD), (4) med-
ication use [taking medication to treat tremor (yes vs. no)], and
(5) additional variables of interest (e.g., age of symptom onset).
The Center for Epidemiological Studies Depression Scale (CESD-
10) was also administered; this is a self-report, 10-item screening
questionnaire for depressive symptoms [range= 0–30 (greater
depressive symptoms)] (10). To further evaluate cognition, the
research assistant administered the Folstein Mini-Mental State
Examination [MMSE, range 0–30 (no impairment) (11)].
A videotaped neurological examination was performed on ET-
PDpatients. This included one test for postural tremor and five for
kinetic tremor (e.g., pouring, drinking) performed with each arm
(12 tests total). A neurologist specializing in movement disorders
(Elan D. Louis) used a reliable and valid clinical rating scale,
theWashingtonHeights-Inwood Genetic Study of ET (WHIGET)
tremor rating scale, to rate postural and kinetic tremor during
each test: (0–3). These ratings resulted in a total tremor score
(range= 0–36).
Diagnoses
Each patient had received a diagnosis of PD or ET-PD from
their treating movement disorders neurologist at the Institute. In
addition, based on office record review, the diagnosis of PD was
confirmed (Elan D. Louis) prior to enrollment using published
diagnostic criteria, which required the presence of at least two
cardinal signs (12). The diagnosis of ET-PD was further reviewed
prior to enrollment, and required that (1) the ET diagnosis was
present for at least 5 years prior to the PD diagnosis, (2) the
initial ET was characterized by moderate or greater amplitude
kinetic tremor in the absence of any signs of PD (e.g., rest tremor,
bradykinesia), and (3) the initial ET diagnosis occurred in absence
of red flags for possible emerging PD (isolated postural tremor
without kinetic tremor, unilateral kinetic tremor).
Final Subject Selection
Data were available on all 30 enrolled ET-PD patients. These were
compared to data on 53 PD patients who had been frequency-
matched to the ET-PD patients by age.
Statistical Analyses
Data were analyzed in SPSS (Version 21). Demographical and
clinical characteristics of ET-PD and PD patients were compared
using chi-squared tests, Fisher’s exact tests, Student’s t-tests and,
when the variable was not normally distributed, Mann–Whitney
tests (Table 1). The MMSE score and the TICS score were not
normally distributed (respective Kolmogorov–Smirnov z= 2.17,
p< 0.001 and z= 1.53, p= 0.02). Therefore, correlations between
these scores and other variables were assessed with Spearman’s
correlation coefficients. TheMMSEwas not normally distributed,
even after log transformation and other forms of transformation
(squaring, cubing). By contrast, after transformation as follows:
log10(41 TICS score), the TICS score was normally distributed
(Kolmogorov–Smirnov z= 1.08, p= 0.19). In a linear regression
analysis, we assessed the association between disease duration
and transformed TICS score (outcome variable), adjusting for
age and education. To explore the possibility of confounding by
education, in a linear regression model, we assessed the associ-
ation between diagnosis and transformed TICS score (outcome
variable), adjusting for years education.
Following previously published guidelines (13, 14), the MMSE
was divided into subscores, reflecting different cognitive domains.
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TABLE 1 | Demographical and clinical characteristics of participants.
PD ET-PD Significance
n 53 30
Age (years) 76.53.4 77.57.6 p= 0.51a
Female gender 24 (45.3) 11 (36.7) p=0.45b
Non-Hispanic white 48 (90.6) 26 (86.7) p= 0.72c
Education (years) 16.52.7 15.14.4 p= 0.12a
Disease duration (years) 9.912.5
(6.0)
32.322.1
(28.0)
p<0.001d
CIRS score 8.03.4 8.43.7 p= 0.67a
CESD-10 score 9.55.3 9.15.8 p= 0.79a
Total tremor score NA 24.05.3 NA
Total number of prescription
medications
6.52.9 6.33.4 p= 0.77a
Takes medication for ET NA 22 (73.3) NA
Number of medications for ET NA 1.0 0.8
(0–3)
NA
Takes medication with
GABA-ergic properties
2 (3.8) 8 (26.7) p= 0.004c
Takes dopamine agonist 9 (17.0) 4 (13.3) p= 0.76c
Takes amantadine 3 (5.7) 2 (6.7) p= 1.00c
Takes selegiline 13 (24.5) 2 (6.7) p=0.04b
Takes anticholinergic agent 0 (0.0) 0 (0.0) p=1.00b
Takes carbidopa–levodopa 45 (84.9) 15 (50.0) p= 0.001b
Carbidopa–levodopa dose
(mg)e
337.9342.1
(200)
486.7274.8
(300)
p=0.02d
Years on
carbidopa–levodopae
6.14.3 5.94.3 p=0.88d
Values are meanSD (median or range) or number (percentage).
CESD-10, Center for Epidemiological Studies Depression Scale; CIRS, Cumulative Illness
Rating Scale; ET, essential tremor; GABA, gamma aminobutyric acid; mg, milligrams; NA,
not applicable; PD, Parkinson’s disease.
aStudent’s t-test.
bChi-squared test.
cFisher’s exact test.
dMann–Whitney test.
eAmong participants taking carbidopa–levodopa.
NA, not applicable.
To add to the robustness of our analyses, MMSE subscores were
combined with TICS subscores reflecting the same cognitive
domains, except for delayedmemory, which is available only from
theMMSE. The final subscores were orientation (combined), lan-
guage (combined), working memory (combined), delayed mem-
ory (from theMMSE), andmotor/construction (from theMMSE).
Results
Parkinson’s disease and ET-PD patients were similar in age, gen-
der, race, and education (Table 1). As expected, disease duration
was longer in ET-PD than PD. The two groups were similar
in terms of CIRS score, CESD-10 score, and total number of
prescription medications (Table 1). A higher proportion of PD
than ET-PD patients was taking carbidopa–levodopa, although
the daily dose (miiligrams) of levodopa was higher in ET-PD
(Table 1). A higher proportion of ET-PD than PD patients were
takingmedications with gamma aminobutyric acid (GABA)-ergic
properties (e.g., primidone, benzodiazepines). The Hoehn and
Yahr score was I or II in 85% of cases.
The TICS score was lower in ET-PD than PD (p< 0.001,
Table 2; Figure 1). The MMSE score was lower in ET-PD than
PD (p= 0.001, Table 2; Figure 2). The orientation subscore was
lower in ET-PD than PD (p< 0.001, Table 2), as was the language
TABLE 2 | Cognitive performance of participants.
PD ET-PD Significance
n 53 30
TICS score 35.02.0 (35.0) 31.73.9 (32.0) p<0.001a
MMSE score 28.42.2 (29.0) 26.53.1 (28.0) p= 0.001a
Subscores
Orientation 19.80.8 (20.0) 19.11.5 (20.0) p<0.001a
Language 9.90.3 (10.0) 9.01.0 (9.0) p<0.001a
Working memory 14.21.5 (15.0) 12.33.1 (14.0) p= 0.001a
Delayed memory 2.11.0 (2.0) 1.80.9 (2.0) p= 0.06a
Motor/construction 1.80.5 (2.0) 1.70.6 (2.0) p= 0.22a
Values are meanSD (median).
ET, essential tremor; MMSE, Folstein Mini-Mental State Examination; PD, Parkinson’s
disease; TICS, telephone interview for cognitive status.
aMann–Whitney test.
FIGURE 1 | TICS score in ET-PD vs. PD. The central circles represent
means and the bars represent the 95% confidence intervals.
FIGURE 2 |MMSE score in ET-PD vs. PD. The central circles represent
means and the bars represent the 95% confidence intervals.
subscore (p< 0.001, Table 2) and the working memory sub-
score (p= 0.001, Table 2). The delayed memory subscore was
marginally lower in ET-PD than PD (p= 0.06, Table 2). The
two groups did not differ with respect to the motor/construction
subscore (p= 0.22, Table 2).
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The MMSE and TICS scores were highly correlated (Spear-
man’s r= 0.63, p< 0.001). Both scores were inversely correlated
with disease duration (for MMSE score, Spearman’s r= 0.46,
p< 0.001, Figure 3; for TICS score, Spearman’s r= 0.53,
p< 0.001, Figure 4) and age (for MMSE score, Spearman’s
r= 0.36, p= 0.001; for TICS score, Spearman’s r= 0.40,
p< 0.001) and were correlated with years of education (forMMSE
score, Spearman’s r= 0.35, p= 0.002; for TICS score, Spearman’s
r= 0.30, p= 0.008). In a linear regression analysis, disease dura-
tion (β= 0.07, p< 0.001), age (β= 0.13, p= 0.047), and educa-
tion (β= 0.29, p= 0.004) were independently associated with
transformed TICS score.
Years of education in ET-PD patients was 15.1 4.4 vs.
16.5 2.7 in PD patients (p= 0.12, Table 1). To explore the pos-
sibility of confounding by education, in a linear regression model,
we assessed the association between diagnosis and transformed
TICS score (outcome variable), adjusting for years education. In
that model, the transformed TICS score remained lower ET-PD
than PD patients (β= 0.16, p< 0.001), even after adjusting for
years of education. A similar linear regression model, examining
the association between MMSE and diagnosis, was not possible
because the MMSE was not normally distributed.
FIGURE 3 |MMSE score by disease duration (years). The regression line
is shown.
FIGURE 4 | TICS score by disease duration (years). The regression line is
shown.
There was no correlation between Hoehn and Yahr score and
cognitive test scores; in ET-PD patients, there was no correlation
between total tremor score and cognitive test scores (data not
shown).
There was no difference in cognitive scores between ET-PD
patients who were taking medication with GABA-ergic prop-
erties vs. ET-PD patients who were not taking such medica-
tion (for MMSE score, Mann–Whitney= 0.19, p= 0.85; for TICS
score, Mann–Whitney= 0.85, p= 0.40). There was no differ-
ence in cognitive scores between ET-PD patients who were tak-
ing carbidopa–levodopa vs. ET-PD patients who were not (for
MMSE score, Mann–Whitney= 0.56, p= 0.58; for TICS score,
Mann–Whitney= 0.006, p= 0.996). Among patients who were
taking carbidopa–levodopa, there was no correlation between
daily dose (milligrams) and cognitive test scores (for MMSE
score, Spearman’s r= 0.18, p= 0.18; for TICS score, Spearman’s
r= 0.18, p= 0.19).
To assess whether the group difference in cognitive test scores
was an artifact of difference in disease duration, in a sensitivity
analysis, we frequency-matched 48 PD and 11 ET-PD patients by
both disease duration [9.9 12.5 years (PD) vs. 10.6 5.2 (ET-
PD), t-test= 0.18, p= 0.86]; in these analyses, both cognitive test
scores were lower in ET-PD than PD [for MMSE score, 27.3 2.2
(median= 28.0) in ET-PD vs. 28.4 2.2 (median= 29.0) in
PD, Mann–Whitney= 2.21, p= 0.027; for TICS score, 33.0 2.9
(median= 34.0) in ET-PD vs. 35.0 2.0 (median= 35.0) in PD,
Mann–Whitney= 2.17, p= 0.03].
Discussion
As part of a prospective, clinical–epidemiological study, ET-PD
and PD patients underwent two tests of global cognition and
we tested the a priori hypothesis that ET-PD patients would
have poorer performance than their counterparts with PD alone.
The data, which showed that performance on both cognitive
tests was poorer in ET-PD than in PD, supported this hypoth-
esis. That is, the presence of the combined diagnosis seemed
to be associated with additive cognitive effects. The difference
between the two patient groups was apparent with two dis-
tinct cognitive tests, thereby providing construct validity for the
results.
These data have a number of clinical implications. The first
is that patients with the combined diagnosis may be more likely
to experience cognitive difficulty than those with PD alone, and
clinicians should be sensitive to this issue. The second implication
is that it is possible that this subgroup of patients (i.e., ET-PD) is at
greater risk of developing dementia. These data; however, do not
directly address this question.
The ET-PD group performed more poorly in several domains
(orientation, language, working memory, and marginally in
delayed memory). This observed mixture of differences does not
simply reflect a greater degree of subcortically driven deficits in
the ET-PD group, but also reveals greater impairment in abilities
more typically affected by cortical conditions such as Alzheimer’s
disease (13). More comprehensive neuropsychological testing is
needed to examine the potentially heterogeneous combination of
processes that contribute to the cognitive performance issues in
patients with the combined diagnosis.
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The ET-PD patients had a longer duration of symptoms than
the PD patients, as one would have expected – they had had ET for
a minimum of 5 years prior to the onset of PD.When we matched
the two groups based on duration of symptoms, the difference in
cognitive test scores persisted, indicating that symptom duration
was not a confounding factor. We did not collect data on duration
of PD per se; however, the number of years on carbidopa–levodopa
did not differ between the ET-PD and PD groups, suggesting that
the duration of PD was likely to have been similar in the two
groups.
This study should be interpreted within the context of several
limitations. First, cognition was evaluated using two brief, global
screening instruments rather than a detailed neuropsychological
test battery. Despite this limitation, several significant differences
were evident; a more detailed cognitive assessment would likely
reveal additional differences. Second, the studywas designed prior
to the widespread use of the Montreal Cognitive Assessment,
which is more sensitive to deficits in executive function, and it
would be useful in future studies to employ this cognitive screen
as well. Finally, we did not collect data on the ON or OFF state
of patients and could not assess the potential influence of current
motor state on test performance.
This study had several strengths. It is the first to address this
particular research question and this specific a priori hypothesis,
thereby adding another unique data element to our understanding
of cognition in ET. Second, a standardized assessment was per-
formed on all study participants by a research worker who was
blinded to the a priori study hypothesis. Third, participants were
enrolled prospectively, thereby avoiding the issue of incomplete
data inherent in a retrospective chart review.
In summary, the performance on both cognitive tests and sev-
eral test subscores was poorer in patients with ET-PD than in PD.
That is, the presence of the combined diagnosis, ET-PD, seemed
to be associated with additive cognitive effects.
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